VRTX Vertex Pharmaceuticals Incorpor | US92532F1003
Financials
Trends
Details
| Breakdown | 31.12.2027 | 31.12.2026 | Change % |
|---|---|---|---|
| Total Revenue | 14.347.460.320 | 13.046.091.890 | 9.98% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| Operating Expense | -- | -- | -- |
| Selling General and Administrative | -- | -- | -- |
| Research & Development | -- | -- | -- |
| Operating Income | -- | -- | -- |
| Pretax Income | -- | -- | -- |
| Net Income Common Stockholders | -- | -- | -- |
| Basic EPS | 21,31 | 18,96 | 12.40% |
| Diluted EPS | -- | -- | -- |
| Analyst Count | 18 | 19 | 5.26% |
| EBIT | -- | -- | -- |
| EBITDA | -- | -- | -- |